Edison Investment Research - JDC Group AG (JDC) JDC Group - Large contracts start to materialise

Report

Edison Investment Research

Pedro Fonseca

JDC Group - Large contracts start to materialise

JDC Groupâ€™s (JDC) efforts to develop its digital platform to provide administrative and sales support and to stimulate its clientsâ€™ bancassurance business have started to drive earnings. As new contracts are onboarded, JDC should further strengthen its market position and also leverage the broader trend where traditional financial institutions enter into partnerships with fintechs. Prudent cost management and the ability to efficiently scale up the platform are key aspects to track going forward.

04/09/2019 5 EN

Underlying

JDC Group AG

JDC Group AG. JDC Group AG, formerly Aragon AG, is a Germany-based financial services company that offers brokerage financial products and consultancy services. The Company's business is divided into two business segments: Advisory and AdvisorTech. The Advisory segment provides financial products of its subsidiaries Jung, DMS & Cie. and FiNUM to end customers via independent consultants, brokers and financial service providers. In addition, this segment also operates a managed portfolio of investment funds, closed-end funds, certificates, insurance policies and other financial products. The AdvisorTech segment provides information technology (IT) and management consulting services. The Company is active in Germany and Austria. JDC Group AG operates Jung, DMS & Cie, FiNUM. Private Finance AG (Austria), FiNUM Private Finance AG (Germany) and FiNUM. Finanzhaus AG as subsidiaries.

See profile

DE000A0B9N37 Germany

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Pedro Fonseca

Other Reports on these Companies

Edison Investment Research

JDC Group - Accelerating again in FY24

JDC Group (JDC) reported FY23 results that were in line with the preliminary results published on 8 March. After a very strong Q423, JDC expects FY24 revenue growth to accelerate to c 17% (FY23: 10.0%) and EBITDA to grow by 36% (FY23: 30.2%) at the midpoint of guidance. To reach the FY25 target of €246m in revenue, JDC also needs 17% top-line growth in FY25. JDC trades at an FY25e EV/EBITDA multiple of 13.7x on our estimates, which we believe is undemanding for what is essentially a fast-scaling platform business. Our DCF provides a valuation of €34.04/share (versus €34.09/share previously).

April 8, 2024 April 8, 2024 1 EN

EQS Group AG

EQS-News: JDC Group AG bestätigt vorläufige Zahlen 2023

EQS-News: JDC Group AG / Schlagwort(e): Jahresbericht JDC Group AG bestätigt vorläufige Zahlen 2023 28.03.2024 / 08:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. JDC Group AG bestätigt vorläufige Zahlen 2023 Umsatz 2023 wächst um 10 Prozent auf 171,7 Mio. EUR EBITDA steigt um rund 31 Prozent auf 11,7 Mio. EUR nach 9,0 Mio. EUR im Vorjahr Für 2024 wird eine deutliche Umsatz- und Gewinnsteigerung erwartet Die JDC Group AG (ISIN DE000A0B9N37) hat ihre Finanzzahlen 2023 veröffentlicht und bestätigt damit die am 8. März ver...

March 28, 2024 March 28, 2024 1 DE

EQS Group AG

EQS-News: JDC Group AG confirms preliminary figures for 2023

EQS-News: JDC Group AG / Key word(s): Annual Report JDC Group AG confirms preliminary figures for 2023 28.03.2024 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. JDC Group AG confirms preliminary figures for 2023 Revenues in 2023 grow by 10 percent to EUR 171.7 million EBITDA increases by around 31% to EUR 11.7 million after EUR 9.0 million in the previous year Significant revenue and earnings growth expected for 2024 JDC Group AG (ISIN DE000A0B9N37) has published its financial figures for 2023, confirming the preliminary ...

March 28, 2024 March 28, 2024 1 EN

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

14h / 58m 14h / 58m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

15h / 10m 15h / 10m 1 EN

Martyn King

Martyn King

Foxtons Group - FY24 underpinned by market share gains

Foxtons Group’s Q1 revenue grew by 9%, supported by growth in all three divisions as the strategic initiatives continue to gain significant momentum, driven by investment in staff, best-in-class bespoke IT and data platforms. This implies that Foxtons’ medium-term targets are now coming into focus. Market share is being gained in all divisions, which puts Foxtons in a good position as the sales market stabilises. We maintain our valuation of 132p/share and believe that if interest rates stabilise or ease further, there are upside risks to our forecasts.

15h / 28m 15h / 28m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

JDC Group - Large contracts start to materialise

JDC Group - Accelerating again in FY24

EQS-News: JDC Group AG bestätigt vorläufige Zahlen 2023

EQS-News: JDC Group AG confirms preliminary figures for 2023

Ultimovacs - Steadfast commitment to UV1 progression

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

Foxtons Group - FY24 underpinned by market share gains

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe